RNAi Message Board - Msg: 20381150

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : RNAi

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who started this subject	8/5/2004 12:15:58 PM
From: bob zagorin	of 671

from isis report today. mgt said they will broadly participate with alnylam and share in essentially all ALNY RNAI revenues. more detail on conf. call.. "...Earned a $500,000 license fee from Alnylam related to Alnylam's recently established alliance with Merck to develop and commercialize RNAi therapeutics for ocular diseases. This license fee was the first payment to Isis from its participation in fees from Alnylam's partnering programs under the companies' strategic alliance formed in March 2004 to develop and commercialize RNAi therapeutics. Under the terms of the agreement, Isis licensed to Alnylam its patent estate relating to antisense mechanisms and oligonucleotide chemistry for double-stranded RNAi therapeutics in exchange for a $5 million technology access fee, participation in fees for Alnylam's partnering programs, as well as downstream milestone and royalty payments...."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next